Efficacy and immunogenicity of different BCG doses in BALB/c and CB6F1 mice when challenged with H37Rv or Beijing HN878,bioRxiv - Immunology

当前位置： X-MOL 学术 › bioRxiv. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy and immunogenicity of different BCG doses in BALB/c and CB6F1 mice when challenged with H37Rv or Beijing HN878
bioRxiv - Immunology Pub Date : 2020-10-21 , DOI: 10.1101/2020.10.21.349373
Bhagwati Khatri , James Keeble , Belinda Dagg , Daryan A. Kaveh , Philip J. Hogarth , Mei Mei Ho

In this study, 2 strains of mice (BALB/c and CB6F1) were vaccinated with a range of Bacille Calmette Guerin (BCG) Danish doses from 300,000 to 30 CFU/mouse, followed by either immunogenicity evaluation or aerosol infection with Mycobacterium tuberculosis (a laboratory strain H37Rv or West-Beijing HN878 strain). The results indicated that both strains of mice when infected with HN878 exhibited significant protection in their lungs with BCG doses at 300,000 to 3000 CFU (BALB/c) and 300,000 to 300 CFU (CB6F1). Whereas, both strains of mice when infected with H37Rv, significant protection was seen in BCG doses at 300,000 to 300 CFU. Immunological evaluation revealed interesting results; i) both strains of mice demonstrated a significant increase in the frequencies of BCG specific IFN[gamma]+ IL2+ TNF[alpha]+ CD4 T cells in the BCG doses at 300,000 to 3000 CFU (BALB/c) and 300,000 to 300 CFU (CB6F1); ii) secretion of IL2 and IFN[gamma]; were correlated with the bacterial burden in the lungs of HN878 infected CB6F1 mice. The study demonstrated a BCG dose at 3000 CFU (an equivalent single human dose in the mice by body weight index) is protective in both strains of mice and the use of a virulent clinical isolate in testing new tuberculosis vaccine/advancing research is recommended.

更新日期：2020-10-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文